Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nuplazid for neuropsychiatric symptoms in neurodegenerative disease
NCT03575052Phase 3Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- May 2018
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of pimavanserin in neurodegenerative disease, sponsored by Acadia Pharmaceuticals. Started May 2018; status: completed.
02
Drugs
pimavanserin
03
Conditions
neurodegenerative disease
Beyond the preview
Go deeper on NCT03575052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03575052.